GlassScriptPhysician profile
Marc A Herschelman
NPI 1538193339
$4,832.22
in general payments reported to CMS, 2019-2025
28 companies · $1,715 in 2025
The $1,715 reported for 2025 was more than what 75% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $574 · 2020: $122 · 2021: $149 · 2022: $252 · 2023: $785 · 2024: $1,235 · 2025: $1,715.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,682 · Education: $53.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,681.98 |
| Education | $53.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,619.95 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $768.10 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $294.19 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Phathom Pharmaceuticals, INC. | $219.54 | 2024-2025 | Voquezna |
| Pfizer INC. | $209.60 | 2019-2025 | |
| Braintree Laboratories, INC. | $169.00 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $168.41 | 2025 | Zenpep |
| Regeneron Healthcare Solutions, INC. | $156.31 | 2022-2024 | Dupixent |
| Allergan, INC. | $154.13 | 2019 | |
| Biotronik Nro, INC. | $143.02 | 2024 | Prospera |
| Abbott Laboratories | $133.96 | 2021-2025 | Eterna, Freestyle Libre 3, Proclaim |
| Genzyme Corporation | $123.61 | 2022-2025 | |
| Janssen Biotech, INC. | $108.93 | 2020-2025 | Tremfya, Stelara |
| Merck Sharp & Dohme LLC | $72.14 | 2019-2024 | Dificid |
| Qol Medical, LLC | $66.64 | 2025 | Sucraid |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $62.93 | 2022-2025 | Ibsrela |
| Celgene Corporation | $57.54 | 2022-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $47.37 | 2025 | |
| Celltrion USA INC. | $41.76 | 2024-2025 | Vegzelma, Zymfentra |
| Lilly USA, LLC | $40.46 | 2025 | Omvoh |
| Janssen Pharmaceuticals, INC | $28.62 | 2019 | |
| Ucb, INC. | $25.84 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $23.89 | 2021 | |
| Exact Sciences Corporation | $23.43 | 2024 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $20.93 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.05 | 2023 | Cyltezo |
| Novo Nordisk INC | $17.95 | 2025 | Wegovy |
| Echosens North America, INC. | $14.92 | 2025 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Herschelman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.